Pharmaceuticals News and Research

RSS

Quintiles opens expanded research facility in London

Quintiles today announced the opening of its expanded research facility in London, UK, increasing its Phase I capacity and extending its ability to drive progress in translational medicine.

8 Mar 2010

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week March 8-14 is the time for the nation to go orange and move it to end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year MS Awareness Week and the state of MS research aptly coincide. Move it to create a world free of MS!

8 Mar 2010

UTSA celebrates grand opening of NVI facility in the greater San Antonio region

The University of Texas at San Antonio celebrates the grand opening of its New Venture Incubator, a facility with laboratory, office and meeting spaces to support technology start-ups in the greater San Antonio region. The incubator, housed on UTSA’s Main Campus, will serve as a bridge between San Antonio entrepreneurs and the region’s research and development community.

8 Mar 2010

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

Entelos, Inc., a simulation and modeling company focused on human health, and RegeneMed, Inc., a tissue-based drug discovery and regenerative medicine company, announced today the release of iToxFX™.

8 Mar 2010

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Cell Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has completed its inspection of the facility at NerPharMa (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy), which manufactures the CTI's drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product.

8 Mar 2010

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at the 56th annual meeting of the ORS in New Orleans, LA.

8 Mar 2010

Leadership challenges and best practices in dealing with FDA’s REMS

Three pharmaceutical executives with extensive experience in dealing with the FDA’s Risk Evaluation and Mitigation Strategy (REMS) will share their thoughts and practices at an open industry webinar at 12 noon EST on Wednesday, March 10, sponsored by ParagonRx.

6 Mar 2010

PPA: Assistance programs for uninsured and financially struggling patients

An article in the Times Courier recently highlighted the Partnership for Prescription Assistance (PPA), a group that has helped more than 6 million uninsured and financially struggling patients find assistance programs that provide the medicines they need for free or nearly free.

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Merriman Curhan Ford Group, Inc. was a co-manager in Anthera Pharmaceuticals, Inc.'s public offering of 6.0 million shares of common stock.

6 Mar 2010

Inpatient integrative medicine program can have significant impact on pain: Study

Non-traditional therapies relieve pain among a wide range of hospitalized patients as much as 50 percent, according to a first-of-a-kind study in the Journal of Patient Safety.

6 Mar 2010

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at the 2010 American Society of Clinical Oncology's Genitourinary Cancers Symposium in San Francisco, CA.

6 Mar 2010

La Jolla Pharmaceutical, Adamis Pharmaceuticals to terminate merger agreement

La Jolla Pharmaceutical Company today announced that La Jolla and Adamis Pharmaceuticals Corporation have agreed to terminate their merger agreement relating to the proposed merger of the two companies.

6 Mar 2010

Poll: On health reform, Americans trust Obama more than both parties in Congress

A new Gallup poll asked Americans whom they trusted to reform the nation's health care system.

5 Mar 2010

AMICAS and Merge Healthcare sign definitive merger agreement

AMICAS, Inc. and Merge Healthcare Incorporated (Nasdaq: MRGE) today announced that they will enter into a definitive merger agreement pursuant to which Merge will acquire all of the outstanding shares of AMICAS for $6.05 per share in cash, or an aggregate of $248 million.

5 Mar 2010

Varian launches next generation dissolution apparatus

Varian, Inc. announced today the availability of its next generation dissolution apparatus designed for testing tablets, capsules and other dosage forms. The 708-DS supports a broad set of applications ranging from manual dissolution testing to automated, high-throughput analysis. It provides extensive flexibility to match the needs of individual laboratories, whether in research or testing. Integration with either the new Varian UV or LC Dissolution Systems will save time and reduce the potential for sample handling errors.

5 Mar 2010

NanoViricides files Universal Form S-3 Shelf Registration with SEC

NanoViricides, Inc., reports that it has filed a “Universal Form S-3 Shelf Registration” with the Securities and Exchange Commission for the sale from time to time of up to $40 million of its securities. The Company recently became eligible to file a shelf registration to register its securities.

5 Mar 2010

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2009 and provided an update on its progress.

5 Mar 2010

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105). Results from REGION-I demonstrated treatment with PEP005 Gel once daily for 2 consecutive days.

5 Mar 2010

DUSA Pharmaceuticals to unveil BLU-U Blue Light Photodynamic Therapy Illuminator at AAD meeting

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, will unveil an ergonomically enhanced BLU-U® Blue Light Photodynamic Therapy Illuminator at this year's American Academy of Dermatology meeting in Miami, Florida, March 5-9. BLU-U, in conjunction with the Levulan® Kerastick® topical treatment, is an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform.

5 Mar 2010

Pharmaceuticals News and Research

Quintiles opens expanded research facility in London

MS Awareness Week: Time for nation to go orange and move it to end MS

UTSA celebrates grand opening of NVI facility in the greater San Antonio region

Entelos, RegeneMed release iToxFX to screen novel compounds for potential toxicity issues

NerPharMa facility receives FDA approval to manufacture CTI's drug pixantrone

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Leadership challenges and best practices in dealing with FDA’s REMS

PPA: Assistance programs for uninsured and financially struggling patients

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Anthera Pharmaceuticals' 6.0M common stock public offering: Merriman Curhan Ford acts as co-manager

Inpatient integrative medicine program can have significant impact on pain: Study

Poniard Pharmaceuticals' picoplatin Phase 2 study in metastatic CRPC: Positive results

La Jolla Pharmaceutical, Adamis Pharmaceuticals to terminate merger agreement

Poll: On health reform, Americans trust Obama more than both parties in Congress

AMICAS and Merge Healthcare sign definitive merger agreement

Varian launches next generation dissolution apparatus

NanoViricides files Universal Form S-3 Shelf Registration with SEC

Opexa Therapeutics reports net loss of $1,433,922 for year ended December 31, 2009

LEO Pharma presents Phase III study results of PEP005 Gel 0.05% for treatment of AK at 68th AAD meeting

DUSA Pharmaceuticals to unveil BLU-U Blue Light Photodynamic Therapy Illuminator at AAD meeting

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring